YFYufan Feng

Yufan Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yufan Feng has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Chi Geng

    Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People’s Republic of China

    2 shared publications
  • Danica Chen

    Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, CA 94720, USA; Metabolic Biology Graduate Program, University of California, Berkeley, Berkeley, CA 94720, USA; Endocrinology Graduate Program, University of California, Berkeley, Berkeley, CA 94720, USA

    2 shared publications
  • Yifei Wang

    Department of Metabolic Biology and Nutrition, University of California, Berkeley, USA

    2 shared publications
  • Chih-Ling Wang

    Department of Metabolic Biology and Nutrition, University of California, Berkeley, USA

    1 shared publication
  • Chih‐Ling Wang

    Department of Nutritional Sciences and Toxicology University of California Berkeley California USA

    1 shared publication
  • Hongfan Chen

    Department of Cardiology The Second Affiliated Hospital of Soochow University Suzhou 215004 Jiangsu China suda.edu.cn

    1 shared publication

Latest Publications

  • Open Access

    Late-life semaglutide treatment slows ageing and extends lifespan in female mice

    by Yufan Feng, Marine Barthez, Yifei Wang, Yibing Chen, Huixian Qiu, Chih-Ling Wang, Kartoosh Heydari, Melaine Delcroix, Lene Juel Rasmussen, Vilhelm A. Bohr, et al.

    Pharmacological glucagon-like peptide-1 receptor (GLP-1R) activation reduces food intake and is an effective therapy for type 2 diabetes and obesity 1 . The use of GLP-1 medicines has revealed pleiotropic beneficial effects beyond glucose and weight control 2–5 , but little is known about the underlying basis of the pleiotropic effects. Here, treatment of 20-month-old female C57BL/6 mice with the GLP-1R agonist semaglutide for 3 months improved physiological function, attenuated hallmarks of ageing and modulated nutrient sensors and conserved genetic regulators of ageing. Continued treatment extended mouse lifespan. These effects parallel key features of calorie restriction, a dietary intervention that slows ageing, extends lifespan and alleviates a wide spectrum of ageing-associated diseases 6 . In a longitudinal study in direct comparison to matched calorie restriction, semaglutide treatment preserved baseline function and recapitulated many functional benefits of calorie restriction by attenuating age-associated decline, while also producing improvements above baseline and more favourable trajectories than calorie restriction in exploratory drive, spatial memory and glucose control. Together, these findings demonstrate that GLP-1R activation initiated late in life slows ageing and extends lifespan in female mice, supporting its function as a calorie restriction mimetic and providing a mechanistic framework that may help to explain its broad beneficial effects while revealing effects beyond those attributable to reduced calorie intake.


  • Open Access

    Depression and Heart Failure With Preserved Ejection Fraction: An Inflammatory Perspective

    by Hongfan Chen, Nan Zhang, Yufan Feng, Mengxing Tao, Chi Geng

    Depression is a common comorbidity in patients with heart failure with preserved ejection fraction (HFpEF), suggesting potential epidemiological and pathophysiological connections between these two age‐related chronic diseases. Extensive clinical evidence demonstrates that depression is closely associated with both the incidence and prognosis of HFpEF. It is currently believed that depression may contribute to the pathogenesis of HFpEF through various interconnected mechanisms, including intestinal dysfunction, endothelial dysfunction, disturbances in fat and energy metabolism, autonomic nervous system dysfunction, hypothalamic–pituitary–adrenal (HPA) axis imbalance, and sex differences. Both conditions often share common comorbidities and genetic predispositions. Notably, inflammation is implicated in all these mechanisms and processes, playing a key role at different stages and facilitating the interaction between the two diseases during their onset and progression. However, the connections between depression and HFpEF have not yet been systematically and thoroughly elucidated. This review aims to comprehensively summarize the associations between depression and HFpEF, focusing particularly on elucidating their interplay in pathogenesis from an inflammation perspective, with special emphasis on the adverse effects of depression on the development of HFpEF. Additionally, we evaluate the management approaches for patients with comorbid depression and HFpEF, which include both pharmacological and nonpharmacological treatments, highlighting that personalized and integrated interventions may offer significant benefits. The review underscores the importance of increased attention and early identification of patients with comorbid depression and HFpEF and is expected to provide valuable insights and guidance for the clinical management of this significant patient population.

  • Open Access

    SIRT2 and NAD + Boosting Broadly Suppress Aging‐Associated Inflammation

    by Marine Barthez, Zehan Song, Yufan Feng, Yifei Wang, Chih‐Ling Wang, Danica Chen

    Aging leads to chronic inflammation that is linked to aging‐associated conditions and diseases. Multiple immune pathways become activated during aging, posing a challenge to effectively reduce aging‐associated inflammation. SIRT2, an NAD + ‐dependent deacetylase, suppresses several immune pathways that become activated during aging and may represent an attractive target to broadly dampen aging‐associated inflammation. Here, we show that SIRT2 deficiency leads to increased inflammation governed by multiple immune pathways and tissue function decline at an old age, while NAD + boosting with 78c suppresses aging‐associated inflammation and improves tissue function. These findings highlight SIRT2 as a master regulator of aging‐associated inflammation and support NAD + boosting as an effective strategy to counteract aging‐associated inflammation and tissue function decline.


  • Spleen-Heart Cross-Talk Through CD23-Mediated Signal Promotes Cardiac Remodeling

    by Yufan Feng, Yang Yang, Hongqin Yang, Jin Shan, Jiaxin Zhang, Qian Chen, Yingge Zhang, Yarong Zhang, Zhiwei Li, Yunfei Xue, et al.

    BACKGROUND: Elevated levels of IgE are implicated in pathological cardiac remodeling. However, the origin of IgE remains unknown. In the current study, we aim to explore the source of IgE and the mechanisms underlying IgE production in the context of pathological cardiac remodeling. METHODS: Flow cytometry was used to assess the changes of IgE-producing B cells in different organs/tissues, including the spleen, lymph nodes, bone marrow, peripheral blood, vasculature, and heart, in mice with cardiac remodeling induced by transverse aortic constriction (TAC). The role of IgE low-affinity receptor FcεRII (Fc epsilon receptor II, also named CD23) in IgE-producing B cells during cardiac remodeling was evaluated in mice with loss-of-CD23 or gain-of-CD23. The therapeutic potential of the CD23-neutralizing antibody was evaluated. The factors involved in organ cross-talk, which regulate IgE production, were identified and validated both in vitro and in vivo. RESULTS: We found that splenic IgE-producing cells were significantly elevated in the TAC mice. CD23, as a negative regulator of IgE production, was decreased in splenic B cells of TAC mice. Global knockout of CD23 in mice aggravated TAC-induced IgE synthesis and cardiac remodeling in vivo. In contrast, global or B-cell–specific CD23 overexpression in mice reduced IgE synthesis and alleviated TAC-induced cardiac remodeling. Mechanistically, CD23 was cleaved by ADAM10 (A disintegrin and metalloproteinase domain 10) in the spleen. Screening assay with data-independent acquisition mass spectrometry–based proteomics and ELISA identified Ltf (lactotransferrin), released from the heart shortly after TAC stimulation, as a contributor to ADAM10 upregulation through binding to Ltf receptor Ncl (nucleolin). Meanwhile, Ltf administration promoted IgE elevation, accompanied by increased ADAM10 expression and decreased CD23 expression in vitro and in vivo. Furthermore, the plasma Ltf levels were positively correlated with TAC-induced cardiac remodeling, serum IgE, and sCD23 (soluble CD23). Consistently, Ltf levels were elevated in patients with heart failure with reduced ejection fraction and also positively correlated with serum IgE and sCD23. CONCLUSIONS: Our findings indicate a critical role of the Ltf-ADAM10-CD23 axis in regulating IgE production through cross-talk between the heart and spleen. The Ltf-ADAM10-CD23 axis may represent new molecular targets for IgE-mediated pathological cardiac remodeling.